Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BenQ Medical Technology (ROCO:4116) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BenQ Medical Technology Forward PE Ratio Related Terms
BenQ Medical Technology Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BenQ Medical Technology Forward PE Ratio Chart
BenQ Medical Technology Annual Data
Trend
Forward PE Ratio
BenQ Medical Technology Quarterly Data
Forward PE Ratio
ROCO:4116 vs ISRG, BDX, MDLN: Forward PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, BenQ Medical Technology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BenQ Medical Technology Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BenQ Medical Technology's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BenQ Medical Technology's Forward PE Ratio falls into.
BenQ Medical Technology Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BenQ Medical Technology (ROCO:4116) has a Forward PE Ratio of 0.00 as of Aug. 24, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BenQ Medical Technology and its competitors. According to the industry distribution chart, BenQ Medical Technology ranks #999999 out of 391 companies in the Medical Devices & Instruments industry.
Is BenQ Medical Technology's Forward PE Ratio too high?
BenQ Medical Technology's current Forward PE Ratio is 0.00. Based on the distribution chart, BenQ Medical Technology ranks #999999 out of 391 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BenQ Medical Technology has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, BenQ Medical Technology ranks #999999 out of 391 companies for Forward PE Ratio. This places BenQ Medical Technology in the lower half of its industry. The industry median Forward PE Ratio is 19.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.87, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BenQ Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BenQ Medical Technology's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$55.07, compared to a current price of NT$39.30 — trading 28.6% below its estimated fair value. The current Forward PE Ratio is 0.00. BenQ Medical Technology's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current Forward PE Ratio is 0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?
Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued.
The current stock price of NT$39.30 is trading 28.6% below its estimated GF Value™ of NT$55.07.
GuruFocus considers BenQ Medical Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4116:
Forward PE Ratio: 0.00
GF Value™: NT$55.07 vs. price of NT$39.30 (28.6% below fair value)
No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
84GF Score
Get the complete analysis for ROCO:4116
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4116 has been successfully added to your 
